301
|
Dickinson T, Fleetwood-Walker SM, Mitchell R, Lutz EM. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 1997; 31:175-85. [PMID: 9179871 DOI: 10.1016/s0143-4179(97)90087-1] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The extracellularly recorded electrophysiological activity of single multireceptive dorsal horn neurons was markedly increased by ionophoretic administration of vasoactive intestinal polypeptide (VIP) or pituitary adenylate cyclase activating polypeptide (PACAP)-38. Some cells responded selectively to PACAP-38 (suggesting mediation by a PACAP receptor), whereas others responded to both VIP and PACAP-38 (suggesting a VIP1 and/or VIP2 receptor). Most non-nociceptive cells were unaffected by PACAP-38 and all were unaffected by VIP. The selectivity of VIP/PACAP receptor antagonists was established on cloned rat VIP1, VIP2 and PACAP receptors in vitro before their utilization to indicate the likely involvement of VIP1, and possibly PACAP receptors, in VIP- and PACAP-38-mediated responses of dorsal horn neurons. The VIP/PACAP receptor antagonists inhibited responses of multireceptive cells to sustained innocuous (brush) and noxious (mustard oil) stimuli, with a selectivity suggesting the involvement of VIP1 and PACAP receptors, although the participation by VIP2 receptors cannot be excluded. These data implicate both VIP and PACAP in regulating the basal responsiveness of multireceptive dorsal horn neurons to sensory stimuli.
Collapse
Affiliation(s)
- T Dickinson
- Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Summerhall, UK
| | | | | | | |
Collapse
|
302
|
Iida-Klein A, Guo J, Takemura M, Drake MT, Potts JT, Abou-Samra A, Bringhurst FR, Segre GV. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. J Biol Chem 1997; 272:6882-9. [PMID: 9054374 DOI: 10.1074/jbc.272.11.6882] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
To define the structural requirements of the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor necessary for activation of phospholipase C (PLC), receptors with random mutations in their second cytoplasmic loop were synthesized, and their properties were assessed. A mutant in which the wild type (WT) rat PTH/PTHrP receptor sequence EKKY (amino acids 317-320) was replaced with DSEL had little or no PTH-stimulated PLC activity when expressed transiently in COS-7 cells, but it retained full capacity to bind ligand and to generate cAMP. This phenotype was confirmed in LLC-PK1 cells stably expressing the DSEL mutant receptor, where both PTH-stimulated PLC activity and sodium-dependent phosphate co-transport were essentially abolished. Individual mutations of these four residues point to a critical role for Lys-319 in receptor-G protein coupling. PTH-generated IPs were reduced to 27 +/- 13% when K319E, compared with the WT receptor, and PLC activation was fully recovered in a receptor revertant in which Glu-319 in the DSEL mutant cassette was restored to the WT residue, Lys. Moreover, the WT receptor and a mutant receptor in which K319R had indistinguishable properties, thus suggesting that a basic amino acid at this position may be important for PLC activation. All of these receptors had unimpaired capacity to bind ligand and to generate cAMP. To ensure adequacy of Galphaq-subunits for transducing the receptor signal, Galphaq was expressed in HEK293 and in LLC-PK1 cells together with either WT receptors or receptors with the DSEL mutant cassette. PTH generated no inositol phosphates (IPs) in either HEK293 or LLC-PK1 cells, when they expressed DSEL mutant receptors together with Galphaq. In contrast, PTH generated 2- and 2. 5-fold increases in IPs, respectively, when these cells co-expressed both the WT receptor and Galphaq. Thus, generation of IPs by the activated PTH/PTHrP receptor can be selectively abolished without affecting its capacity to generate cAMP, and Lys-319 in the second intracellular loop is critical for activating the PLC pathway. Moreover, alpha-subunits of the Gq family, rather than betagamma-subunits, transduce the signal from the activated receptor to PLC, and the PLC, rather than the adenylyl cyclase, pathway mediates sodium-dependent phosphate co-transport in LLC-PK1 cells.
Collapse
Affiliation(s)
- A Iida-Klein
- Endocrine Unit, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA
| | | | | | | | | | | | | | | |
Collapse
|
303
|
Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 1997. [PMID: 8987738 DOI: 10.1523/jneurosci.17-01-00083.1997] [Citation(s) in RCA: 221] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Pituitary adenylate cyclase-activating polypeptides (PACAP-27 and PACAP-38) are neuropeptides of the vasoactive intestinal polypeptide (VIP)/secretin/glucagon family. PACAP receptors are expressed in different brain regions, including cerebellum. We used primary culture of rat cerebellar granule neurons to study the effect of PACAP-38 on apoptosis induced by potassium deprivation. We demonstrated that PACAP-38 increased survival of cerebellar neurons in a dose-dependent manner by decreasing the extent of apoptosis estimated by DNA fragmentation. PACAP-38 induced activation of the extracellular signal-regulated kinase (ERK)-type of mitogen-activated protein (MAP) kinase through a cAMP-dependent pathway. PD98059, an inhibitor of MEK (MAP kinase kinase), completely abolished the antiapoptotic effect of PACAP-38, suggesting that MAP kinase pathway activation is necessary for PACAP-38 action.
Collapse
|
304
|
Du K, Nicole P, Couvineau A, Laburthe M. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. Biochem Biophys Res Commun 1997; 230:289-92. [PMID: 9016768 DOI: 10.1006/bbrc.1996.5949] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
VIP receptors belong to a subfamily of G protein-coupled receptors that includes secretin, glucagon, PTH and several other receptors. We have used site-directed mutagenesis to investigate the requirement of some highly conserved residues in the extracellular loops including aspartate 196 (mutant D196A), leucine 199 (mutant L199A), tryptophane 286 (mutant W286A) and tryptophane 294 (mutant W294A) for the ability of the human VIP1 receptor to bind VIP and to mediate VIP-stimulated cAMP production. After transfection of mutated cDNAs in Cos-7 cells, it appeared that 1) mutants L199A, W286A and W294A bound VIP with the same dissociation constant as the wild-type receptor whereas mutant D196A did not bind 125I-VIP; 2) mutants L199A, W286A and W294A mediate VIP-stimulated cAMP production with the same EC50 as the wild-type receptor whereas VIP displayed a 500-fold decrease of potency in promoting cAMP production through mutant D196A. Since all mutated receptor proteins were expressed and delivered at the plasma membrane (immunofluorescence studies), it is concluded that the first extracellular loop of the human VIP1 receptor contains a highly conserved aspartate residue which is essential for VIP binding and VIP-stimulated cAMP production.
Collapse
Affiliation(s)
- K Du
- Unité de Neuroendocrinologie et Biologie Cellulaire Digestives, INSERMU 410, Faculté de Médecine Xavier Bichat, Paris, France
| | | | | | | |
Collapse
|
305
|
Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides 1997; 18:1539-45. [PMID: 9437714 DOI: 10.1016/s0196-9781(97)00228-3] [Citation(s) in RCA: 157] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The biological effects of VIP are mediated by at least two VIP receptors: the VIP1 and the VIP2 receptors that were cloned in rat, human and mice. As the mRNA coding for each receptor are located in different tissues, it is likely that each receptor modulates different functions. It is therefore of interest to obtain selective agonists for each receptor subtype. In the present work, we achieved the synthesis of two VIP1 receptor selective agonsits derived from secretin and GRF. [R16]chicken secretin had IC50 values of binding of 1,10,000, 20, and 3000 nM for the rat VIP1-, VIP2-, secretion- and PACAP receptors, respectively. This peptide, however, had a weaker affinity for the human VIP1 receptor (IC50 of 60 nM). The chimeric, substituted peptide [K15, R16, L27]VIP(1-7)/GRF(8-27) had IC50 values of binding of 1,10,000, 10,000 and 30,000 nM for the rat VIP1-, VIP2-, secretin- and PACAP receptors, respectively. Furthermore, its also showed an IC50 of 0.8 nM for the human VIP1 receptor and a low affinity for the human VIP2 receptor. It is unlikely that this GRF analogue interacted with a high affinity to the pituitary GRF receptors as it did not stimulate rat pituitary adenylate cyclase activity. The two described analogues stimulated maximally the adenylate cyclase activity on membranes expressing each receptor subtype.
Collapse
Affiliation(s)
- P Gourlet
- Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
306
|
Wu JY, Henins KA, Gressens P, Gozes I, Fridkin M, Brenneman DE, Hill JM. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides 1997; 18:1131-7. [PMID: 9396053 DOI: 10.1016/s0196-9781(97)00146-0] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Previous work has shown that blockade of VIP function in the early postimplantation embryo results in growth retardation and microcephaly. In the present work, the neurobehavioral development of neonatal mice was examined following treatment of dams with a VIP antagonist during this period. Inhibition of VIP functions during early embryogenesis impaired the performance of 5 of 10 developmental behaviors. These behaviors included developmental milestones (first appearance of ear twitch and eye opening) and complex motor behaviors (negative geotaxis, surface righting, and air righting). The retardation of neurobehavioral development produced by inhibition of VIP action indicates that this peptide is important to the progression of embryonic development.
Collapse
Affiliation(s)
- J Y Wu
- Section on Developmental and Molecular Pharmacology, NICHD, NIH, Bethesda, MD 20892, USA
| | | | | | | | | | | | | |
Collapse
|
307
|
Vertongen P, Schiffmann SN, Gourlet P, Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 1997; 18:1547-54. [PMID: 9437715 DOI: 10.1016/s0196-9781(97)00229-5] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Vasoactive Intestinal Polypeptide (VIP) exerts its biological effects through interaction with two high affinity receptors named the VIP1- and the VIP2 receptors. Their messenger RNAs have been mapped in rat brain by in situ hybridization. A cyclic peptide (RO 25-1553) and a secretion analogue ([R16]chicken secretin) were identified as selective agonist peptides for the VIP2- and VIP1 receptors, respectively. The iodinated peptides retained the high affinity and selectivity of the unlabelled peptides and were used for the mapping of each receptor subclass in rat brain. VIP1 receptors were present in the cerebral cortex, the piriform cortex, the claustrum, the caudate-putamen, the dentate gyrus, the lateral amygdaloïd nucleus, the anteroventral thalamic nucleus, the rhomboïd nucleus, the supraoptic nucleus and the choroïd plexus. VIP2 receptors were present in the cerebral cortex, the claustrum, the caudate-putamen, the nucleus accumbens, the lateral septal nuclei, the bed nucleus of the stria terminalis, the basolateral amygdaloïd nucleus, the Ammon's horn, the thalamic nuclei except some centromedial nuclei, the medial habenula, the suprachiasmatic nucleus, the periventricular nucleus, the mammilary nucleus, the superior colliculus and the choroïd plexus.
Collapse
Affiliation(s)
- P Vertongen
- Department of Biochemistry and Nutrition, Faculty of Medicine, Université Libre de Bruxelles, Belgium
| | | | | | | |
Collapse
|
308
|
Abstract
Both pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP type I receptor gene expressions were detected in the corpus luteum of pregnant mare's serum gonadotropin (PMSG)-human chorionic gonadotropin (hCG)-treated immature rats using reverse transcription-polymerase chain reaction (RT-PCR). RT-PCR products of the poly(A)+ RNA extracted from rat corpora lutea yielded dominant DNA bands that corresponded to segments of PACAP mRNA (453 bp) and PACAP type IA receptor mRNA (290 bp) spanned by the PCR primers. The identities of the PACAP cDNA and the PACAP receptor cDNA fragments were confirmed by Southern blot hybridization analyses. Our results showed that PACAP mRNA and PACAP type IA receptor mRNA are synthesized within luteinized cells of rat ovary, and suggest that PACAP is closely linked to the reproductive process.
Collapse
Affiliation(s)
- E Kotani
- Department of Obstetrics and Gynecology, University of Tsukuba, Ibaraki, Japan
| | | | | |
Collapse
|
309
|
Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 1997; 18:1555-60. [PMID: 9437716 DOI: 10.1016/s0196-9781(97)00230-1] [Citation(s) in RCA: 148] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A selective high affinity VIP1 receptor antagonist [Acetyl-His1, D-Phe2, Lys15, Arg16, Leu17] VIP(3-7)/GRF(8-27) or PG 97-269 was synthesized, by analogy with recently obtained selective VIP1 receptor agonists. The properties of the new peptide were evaluated on Chinese hamster ovary (CHO) cell membranes expressing either the rat VIP1-, rat VIP2- or the human VIP2-recombinant receptors and on LoVo cell membranes expressing exclusively the human VIP1 receptor. The IC50 values of 125I-VIP binding inhibition by PG 97-269 were 10, 2000, 2 and 3000 nM on the rat VIP1-, rat VIP2-, human VIP1- and human VIP2 receptors, respectively. PG 97-269 had a negligible affinity for the PACAP I receptor type. It did not stimulate adenylate cyclase activity, but inhibited competitively effect of VIP on the VIP1 receptor mediated stimulation of adenylate cyclase activity. The Ki values were respectively of 15 +/- 5 nM and 2 +/- 1 nM for the rat and human VIP1 receptors. Thus the described molecule in the first reported VIP antagonist with an affinity in the nM range and with a high selectivity for the VIP1 receptor subclass. It may be useful for evaluation of the physiological role of VIP in rat and human tissues.
Collapse
Affiliation(s)
- P Gourlet
- Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Belgium
| | | | | | | | | |
Collapse
|
310
|
Waschek JA, Lelievre V, Bravo DT, Nguyen T, Muller JM. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides 1997; 18:835-41. [PMID: 9285932 DOI: 10.1016/s0196-9781(97)00015-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Neuroendocrine tumors, neuroblastoma in particular, commonly express the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) and their receptors. Retinoic acid (RA) has been shown to induce differentiation of neuroblastoma cell lines, possibly by augmenting or interfering with neuropeptide autocrine loops. We sought to determine which receptor gene subtypes are expressed in selected human neuroblastoma cell lines (SH-SY5Y, IMR-32, and LA-N-5), and the effect of RA on the VIP/PACAP ligand/receptor system. Expression of both PACAP1 and VIP1/PACAP2 receptor genes was detected by Northern analysis, which characteristically encode Type I (PACAP-preferring), and Type II (bivalent VIP/PACAP) receptors, respectively. Binding experiments carried out on IMR-32 cells, using 125I VIP and 125I PACAP-27 as tracers, corroborated that both receptor subtypes were expressed. In contrast to RA upregulation of VIP binding (confirmed here in IMR-32 cells), levels of both receptor mRNAs were reduced after RA treatment. VIP mRNA in each cell line was increased by RA, whereas PACAP mRNA, detected in IMR-32 cells only, was reduced. The studies indicate that several components of the VIP/PACAP autocrine system are regulated in neuroblastoma cell lines during RA differentiation.
Collapse
MESH Headings
- Autocrine Communication
- Gene Expression
- Humans
- Ligands
- Neuroblastoma/metabolism
- Neuropeptides/genetics
- Neuropeptides/metabolism
- Pituitary Adenylate Cyclase-Activating Polypeptide
- RNA, Messenger/metabolism
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
- Receptors, Pituitary Hormone/genetics
- Receptors, Pituitary Hormone/metabolism
- Receptors, Vasoactive Intestinal Peptide/genetics
- Receptors, Vasoactive Intestinal Peptide/metabolism
- Receptors, Vasoactive Intestinal Polypeptide, Type I
- Tretinoin/pharmacology
- Tumor Cells, Cultured
- Up-Regulation/drug effects
- Vasoactive Intestinal Peptide/genetics
- Vasoactive Intestinal Peptide/metabolism
Collapse
Affiliation(s)
- J A Waschek
- Department of Psychiatry, University of California at Los Angeles 90024, USA.
| | | | | | | | | |
Collapse
|
311
|
Abstract
The specific VIP receptor antagonist, [4Cl-D-Phe6,Leu17]VIP, infused i.v. blocked close-intra-arterial infusion of VIP-induced increase in gastric mucosal blood flow (GMBF, measured by the hydrogen gas clearance), and decrease in mean arterial blood pressure while not influencing basal levels in urethane-anesthetized rats. The thyrotropin-releasing hormone (TRH) stable analog, RX 77368, injected intracisternally (IC, 30 ng) increased GMBF and blood pressure. The VIP antagonist did not significantly reduce the GMBF response to IC RX 77368 while enhancing the rise in blood pressure. These findings indicate that [4Cl-D-Phe6,Leu17]VIP is an antagonist for exogenous VIP-induced gastric hyperemia and hypotension and that VIP modulates the systemic blood pressure response to IC RX 77368 at 30 ng while not playing a primary role in the increase of GMBF.
Collapse
Affiliation(s)
- A Király
- CURE/Digestive Disease Research Center, West Los Angeles VA Medical Center, California 90073, USA
| | | | | | | |
Collapse
|
312
|
Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, Robberecht P. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 1997; 18:403-8. [PMID: 9145428 DOI: 10.1016/s0196-9781(96)00322-1] [Citation(s) in RCA: 126] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
RO 25-1553 is a synthetic VIP analogue that induced a long-lasting relaxation of tracheal and bronchial smooth muscles as well as a reduction of edema and eosinophilic mobilization during pulmonary anaphylaxis. In the present study, we tested in vitro the capacity of RO 25-1553 to occupy the different VIP/PACAP receptor subclasses and to stimulate adenylate cyclase activity. The cellular models tested expressed one single receptor subtype: Chinese hamster ovary (CHO) cells transfected with the rat recombinant PACAP I, rat VIP1, and human VIP2 receptors; SUP T1 cells expressing the human VIP2 and HCT 15 and LoVo cells expressing the human VIP1 receptor. RO 25-1553 was threefold more potent than VIP on the human VIP2 receptor, 100- and 600-fold less potent than VIP on the rat and human VIP1 receptors, respectively, and 10-fold less potent than VIP and 3000-fold less potent than PACAP on the PACAP I receptor. RO 25-1553 was a full agonist on the VIP2, the PACAP I, and the rat recombinant VIP1 receptor but a partial agonist only on the human VIP1 receptor. Thus, RO 25-1553 is a highly selective agonist ligand for the VIP2 receptor subclass.
Collapse
MESH Headings
- Adenylyl Cyclases/metabolism
- Amino Acid Sequence
- Animals
- CHO Cells
- Cricetinae
- Enzyme Activation/drug effects
- Humans
- Molecular Sequence Data
- Neuropeptides/chemical synthesis
- Neuropeptides/pharmacology
- Peptides, Cyclic/agonists
- Peptides, Cyclic/pharmacology
- Pituitary Adenylate Cyclase-Activating Polypeptide
- Rats
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Receptors, Pituitary Hormone/drug effects
- Receptors, Vasoactive Intestinal Peptide/chemistry
- Receptors, Vasoactive Intestinal Peptide/drug effects
- Receptors, Vasoactive Intestinal Peptide/metabolism
- Receptors, Vasoactive Intestinal Peptide, Type II
- Receptors, Vasoactive Intestinal Polypeptide, Type I
- Recombinant Proteins
- Transfection
- Tumor Cells, Cultured
- Vasoactive Intestinal Peptide/agonists
- Vasoactive Intestinal Peptide/analogs & derivatives
- Vasoactive Intestinal Peptide/pharmacology
Collapse
Affiliation(s)
- P Gourlet
- Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
313
|
MacKenzie CJ, Lutz EM, McCulloch DA, Mitchell R, Harmar AJ. Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. Ann N Y Acad Sci 1996; 805:579-84. [PMID: 8993443 DOI: 10.1111/j.1749-6632.1996.tb17523.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
MESH Headings
- Animals
- COS Cells
- Cholera Toxin/pharmacology
- Enzyme Activation
- Inositol Phosphates/metabolism
- Pertussis Toxin
- Phospholipase D/metabolism
- Rats
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Receptors, Pituitary Hormone/biosynthesis
- Receptors, Pituitary Hormone/drug effects
- Receptors, Pituitary Hormone/physiology
- Receptors, Vasoactive Intestinal Peptide/biosynthesis
- Receptors, Vasoactive Intestinal Peptide/drug effects
- Receptors, Vasoactive Intestinal Peptide/physiology
- Receptors, Vasoactive Intestinal Peptide, Type II
- Receptors, Vasoactive Intestinal Polypeptide, Type I
- Recombinant Proteins/drug effects
- Recombinant Proteins/metabolism
- Transfection
- Type C Phospholipases/metabolism
- Vasoactive Intestinal Peptide/pharmacology
- Virulence Factors, Bordetella/pharmacology
Collapse
|
314
|
Leech CA, Holz GG, Habener JF. Signal transduction of PACAP and GLP-1 in pancreatic beta cells. Ann N Y Acad Sci 1996; 805:81-92; discussion 92-3. [PMID: 8993395 PMCID: PMC3505615 DOI: 10.1111/j.1749-6632.1996.tb17475.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
PACAP and GLP-1 depolarize pancreatic beta cells and stimulate insulin secretion in the presence of glucose. Depolarization occurs through at least two distinct mechanisms: (1) closure of ATP-sensitive K+ channels, and (2) activation of nonselective cation channels (NSCCs). Under physiological conditions the NSCCs carry a predominantly Na(+)-dependent current. The current may also have a Ca2+ component, but this remains to be determined. Acting together, these two signaling systems reinforce each other and serve to promote membrane depolarization, a rise of [Ca2+]i, and exocytosis of insulin-containing secretory granules. The NSCCs in beta cells are dually regulated by intracellular cAMP and [Ca2+]i. In view of this dual regulation, it appears likely that NSCC channel activation results from signaling events occurring not only at the plasma membrane (gating of channels by cAMP; protein kinase A-mediated phosphorylation of channels) but also at intracellular sites (mobilization of calcium stores by an as yet to be determined process). It is noteworthy that activation of NSCCs has also been reported following stimulation of beta-cells with maitotoxin, or after depletion of intracellular Ca2+ stores. Therefore, the possibility arises that PACAP, GLP-1, and maitotoxin all act on the same types of ion channels in these cells, and that these channels are sensitive to alterations in the content of intracellular calcium. FIGURE 6 summarizes our current knowledge concerning the properties of the PACAP and GLP-1 signaling systems as they pertain to the regulation of NSCCs and intracellular calcium homeostasis in the beta cell. Given that PACAP and GLP-1 are proven to be exceptionally potent insulin secretagogues, it is of considerable interest to determine their usefulness as blood glucose-lowering agents. Initial evaluations of the therapeutic effectiveness of GLP-1 indicate a role for this peptide in the treatment of NIDDM, and also possibly insulin-dependent diabetes mellitus (IDDM). A very attractive feature of such a strategy is the demonstrated lack of hypoglycemic side effects attendant to administration of GLP-1 to diabetic subjects. These observations reinforce the notion that peptides of the PACAP/glucagon/VIP family represent important pharmacological tools for use in experimental therapeutics.
Collapse
Affiliation(s)
- Colin A. Leech
- Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Harvard Medical School and the Howard Hughes Medical Institute, Boston, Massachusetts 02114
| | - George G. Holz
- Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114
| | - Joel F. Habener
- Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Harvard Medical School and the Howard Hughes Medical Institute, Boston, Massachusetts 02114
| |
Collapse
|
315
|
Wei Y, Mojsov S. Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner. Ann N Y Acad Sci 1996; 805:624-7. [PMID: 8993451 DOI: 10.1111/j.1749-6632.1996.tb17531.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Y Wei
- Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021, USA
| | | |
Collapse
|
316
|
Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M. Establishment of a CHO cell clone stably expressing the recombinant human VIP-1 receptor. Ann N Y Acad Sci 1996; 805:570-3. [PMID: 8993441 DOI: 10.1111/j.1749-6632.1996.tb17521.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- P Gaudin
- Laboratoire de Neuroendocrinologie et Biologie Cellulaire Digestives, INSERM U 410, Faculté de Médecine Xavier Bichat, Paris, France.
| | | | | | | | | |
Collapse
|
317
|
Tang H, Sun L, Xin Z, Ganea D. Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP. Ann N Y Acad Sci 1996; 805:768-78. [PMID: 8993475 DOI: 10.1111/j.1749-6632.1996.tb17555.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Neuropeptides, such as VIP and PACAP, released or produced in the microenvironment of the primary and secondary lymphoid organs, could affect a variety of immune responses through the regulation of cytokine expression. VIP has been previously shown to inhibit IL-2, IL-4, and IL-10 production in murine lymphocytes stimulated through the TCR-associated CD3 complex. This study shows that, similar to VIP, PACAP-38 inhibits IL-2 production in T lymphocytes. Comparisons with forskolin, a known cAMP inducer, suggest that the increase in intracellular cAMP represents at least one of the transduction pathways involved in IL-2 inhibition, especially in the higher range of neuropeptide concentration. Studies of the detailed molecular mechanisms involved in the regulation of IL-2 expression indicate that reduction of de novo transcription and destabilization of the message contribute to the reduction of steady-state IL-2 mRNA levels following VIP treatment. Examination of several IL-2 transcriptional factors indicates that only NFAT is down-regulated by VIP. Neuropeptides, such as VIP and PACAP, which specifically modulate the expression of various cytokines, could play an important role in the intricate cytokine network controlling local immune responses.
Collapse
Affiliation(s)
- H Tang
- Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102, USA
| | | | | | | |
Collapse
|
318
|
Pisegna JR, Moody TW, Wank SA. Differential signaling and immediate-early gene activation by four splice variants of the human pituitary adenylate cyclase-activating polypeptide receptor (hPACAP-R). Ann N Y Acad Sci 1996; 805:54-64; discussion 64-6. [PMID: 8993393 PMCID: PMC6736521 DOI: 10.1111/j.1749-6632.1996.tb17473.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide belonging to the VIP/secretin/glucagon family, is present in the hypothalamus, anterior pituitary, and adrenal gland where it regulates hormone release, in the GI tract where it modulates motility, and in human tumoral cell lines where it shows a growth-promoting effect. It is now appreciated that alternative splicing of two exons of the rat PACAP-R gene generate four major rPACAP-R splice variants that are differentially expressed in tissues and variably coupled to intracellular second messengers. Because of the potential implications of these findings in human physiology, we cloned the hPACAP-R gene. Similar to the rat, two exons (SV-1 and SV-2) are alternatively spliced to account for four major hPACAP-R receptor splice variants. These splice variants (hPACAP-R-null, hPACAP-R-SV1, hPACAP-R-SV2, hPACAP-R-SV-3) were cloned from a human frontal cortex cDNA library, stably transfected in NIH/ 3T3 cells and each characterized for ligand affinity, stimulation of adenylate cyclase (AC) and phospholipase C (PLC), and ligand-induced expression of the proto-oncogenes, c-fos, and c-myc. Stably transfected NIH/3T3 cells expressing similar numbers of receptors of the four splice variants showed nearly identical responses for ligand affinity and potency for P-38- and P-27-stimulated increases in cAMP and total inositol phosphates. However, each receptor splice variant differed in their ligand-stimulated efficacy for total inositol phosphate stimulation. The hPACAP-R-SV2 showed the greatest efficacy for stimulating phospholipase C that was approximately seven-fold greater than the hPACAP-R-SV1, twofold greater than the hPACAP-R-Null, and 1.5-fold greater than the hPACAP-R-SV-3 splice variants. To determine whether the splice variants also differ in their ability to stimulate immediate early gene expression, c-fos and c-myc transcripts were assayed by Northern blot and quantified by densitometry. PACAP-38 increased c-fos and c-myc expression for all four of the receptor splice variants that paralleled the efficacy for PLC stimulation, with the the SV-2 splice variant showing the greatest stimulation. These results show that the hPACAP-R-SV2 exhibits enhanced efficacy for coupling to both PLC and activation of the protooncogenes, c-fos and c-myc suggesting a novel and potentially important mechanism for differentially activating signal transduction pathways that influence cellular growth and differentiation.
Collapse
Affiliation(s)
- J R Pisegna
- Digestive Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|
319
|
Waschek JA. VIP and PACAP receptor-mediated actions on cell proliferation and survival. Ann N Y Acad Sci 1996; 805:290-300; discussion 300-1. [PMID: 8993411 DOI: 10.1111/j.1749-6632.1996.tb17491.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J A Waschek
- Department of Psychiatry, University of California at Los Angeles 90024-1759, USA.
| |
Collapse
|
320
|
Inagaki N, Kuromi H, Seino S. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Ann N Y Acad Sci 1996; 805:44-51; discussion 52-3. [PMID: 8993392 DOI: 10.1111/j.1749-6632.1996.tb17472.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide belonging to the vasoactive intestinal polypeptide (VIP)/glucagon/secretin family. We have isolated a third PACAP receptor subtype, designated PACAPR-3, by molecular cloning. The cDNA encoding PACAPR-3 has been isolated from a mouse insulin-secreting beta-cell line MIN6 cDNA library. Mouse PACAPR-3 is a protein of 437 amino acids that has 50% and 51% identity with rat PACAP type I and type II receptors, respectively. We have expressed PACAPR-3 in mammalian cells and Xenopus oocytes. PACAPR-3 binds to VIP as well as PACAP-38 and -27, with a slightly higher affinity for PACAP-38, and is positively coupled to adenylate cyclase. PACAP-38, -27, and VIP evoked Ca2+ activated-Cl- currents in Xenopus oocytes. RNA blotting studies reveal that PACAPR-3 mRNA is expressed widely in tissues and cell lines, including pancreatic islets, insulin-secreting cell lines (MIN6, HIT-T15, and RINm5F), lung, brain, stomach, colon, and heart. Furthermore, insulin secretion from the MIN6 cells is stimulated significantly by PACAP-38 and VIP. The possible mechanisms of insulin secretion by PACAP and VIP are also discussed.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Cloning, Molecular
- Female
- Insulin/metabolism
- Insulin Secretion
- Islets of Langerhans/metabolism
- Islets of Langerhans/physiology
- Mice
- Molecular Sequence Data
- Neuropeptides/pharmacology
- Neurotransmitter Agents/pharmacology
- Oocytes/physiology
- Organ Specificity
- Pituitary Adenylate Cyclase-Activating Polypeptide
- Rats
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
- Receptors, Pituitary Hormone/chemistry
- Receptors, Pituitary Hormone/physiology
- Receptors, Vasoactive Intestinal Peptide/chemistry
- Receptors, Vasoactive Intestinal Peptide/physiology
- Receptors, Vasoactive Intestinal Peptide, Type II
- Sequence Homology, Amino Acid
- Vasoactive Intestinal Peptide/pharmacology
- Xenopus Proteins
- Xenopus laevis
Collapse
Affiliation(s)
- N Inagaki
- Division of Molecular Medicine, Chiba University School of Medicine, Japan
| | | | | |
Collapse
|
321
|
Gonzalez BJ, Basille M, Mei YA, Vaudry D, Fournier A, Cazin L, Vaudry H. Ontogeny of PACAP and PACAP receptors in the rat brain: role of PACAP in the cerebellum during development. Ann N Y Acad Sci 1996; 805:302-13; discussion 313-4. [PMID: 8993412 DOI: 10.1111/j.1749-6632.1996.tb17492.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- B J Gonzalez
- European Institute for Peptide Research (IFRMP No. 23), Laboratory of Cellular and Molecular Neuroendocrinology, INSERM U413, UA CNRS, University of Rouen, Mont-Saint-Aignan, France
| | | | | | | | | | | | | |
Collapse
|
322
|
Braas KM, May V. Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Ann N Y Acad Sci 1996; 805:204-16; discussion 217-8. [PMID: 8993404 DOI: 10.1111/j.1749-6632.1996.tb17484.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The current studies have implicated a prominent role for PACAP peptides in modulating the physiological function of cells derived from the sympathoadrenal lineage. Compared to VIP, both PACAP-27 and PACAP-38 demonstrated potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. The differential effects of PACAP peptides on SCG NPY and catecholamine content and secretion coincided with previous studies that activated directly the sympathetic intracellular cyclic AMP-protein kinase A signaling pathway. These effects appear to be mediated primarily by PACAP1 receptor splice variants coupled to both adenylyl cyclase and phospholipase C in SCG neurons. The actions of PACAP peptides in the SCG shared many parallels with adrenal medullary chromaffin cells, suggesting diverse roles for the PACAP peptidergic system in sympathoadrenal cell development and function. Rather than solutions, these results pose additional questions for the future. What are the endogenous sources of PACAP that regulate sympathetic and adrenal function? Do PACAP peptides, like VIP, have dual roles and also act as sympathetic postganglionic neuromodulators? Are VIP/PACAP receptors expressed during SCG development? What regulates sympathetic PACAP1 receptor isoform expression and how are they differentially coupled to neuronal intracellular signaling cascades? What defines the tissue-specific responses to PACAP-27 and PACAP-38? While many of these questions are not easily approached, future studies of these issues will certainly illuminate the function of PACAP and PACAP receptors in the nervous and endocrine systems.
Collapse
Affiliation(s)
- K M Braas
- Department of Anatomy and Neurobiology, University of Vermont College of Medicine, Burlington 05405, USA
| | | |
Collapse
|
323
|
Lutz EM, MacKenzie CJ, Morrow J, Mitchell R, Bennie J, Carroll S, Clark E, Harmar AJ. Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1. Ann N Y Acad Sci 1996; 805:574-8. [PMID: 8993442 DOI: 10.1111/j.1749-6632.1996.tb17522.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- E M Lutz
- MRC Brain Metabolism Unit, University Department of Pharmacology, Edinburgh, Scotland.
| | | | | | | | | | | | | | | |
Collapse
|
324
|
Hezareh M, Journot L, Bépoldin L, Schlegel W, Rawlings SR. PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells. Ann N Y Acad Sci 1996; 805:315-27; discussion 327-8. [PMID: 8993413 DOI: 10.1111/j.1749-6632.1996.tb17493.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Rat anterior pituitary tissue expresses mRNA for PVR1 and PVR3, as well as a low level of PVR2. The PVR1 appears to be highly expressed in gonadotroph-like cells, while somatotroph-like cells apparently express the PVR3. We have recently demonstrated the expression of mRNA for both PVR2 and PVR3 in corticotroph-like AtT20 cells (FIG.3). If normal corticotrophs express the same mRNA as AtT20 cells, this may partly explain the low levels of PVR2 seen in normal pituitary tissue. Significant levels of at least two PVR1 splice variants mRNAs (PVR1s and PVR1hop) were expressed in clonal gonadotroph-like alpha T3-1 cells and normal rat anterior pituitary tissue. However, these splice variants are reported to have almost identical pharmacological characteristics in terms of binding, and the activation of AC and PLC. Further experiments are necessary to determine the functional consequences of differential splice variant expression in such cells. Interestingly, all three pituitary-cell lines studied expressed mRNA for the PVR3 (FIG.3), whereas earlier binding studies demonstrate a predominance of PACAP-preferring binding sites on normal anterior pituitary-cell membranes. In addition, it is clear that the different PVR subtypes can couple to different intracellular messenger systems. Thus it will be important to determine the expression of the different PVR subtypes in normal anterior pituitary-cell types if we are to begin to understand the regulation of pituitary-cell regulation by PACAP. Such questions form the basis of some of the ongoing studies in our laboratory.
Collapse
Affiliation(s)
- M Hezareh
- Fondation pour Recherches Médicales, University of Geneva, Switzerland
| | | | | | | | | |
Collapse
|
325
|
Gourlet P, Vandermeers A, Vandermeers-Piret MC, De Neef P, Waelbroeck M, Robberecht P. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors. BIOCHIMICA ET BIOPHYSICA ACTA 1996; 1314:267-73. [PMID: 8982281 DOI: 10.1016/s0167-4889(96)00106-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Rabbit secretin, which differs from all other mammalian secretins in having a Leu residue in position 6 (instead of Phe) and a basic residue (Arg) in position 16, had a lower affinity than porcine secretion on recombinant rat secretin receptors but had a greater affinity than porcine secretin on recombinant rat VIP1 and PACAP I receptors. Synthetic [L6] porcine secretin had a reduced potency on secretin and VIP1 receptors whereas [R16] porcine secretin had a similar binding profile as rabbit secretin. Thus, an arginine residue in position 16 reduced 3-fold the affinity of secretin for secretin receptors but increased 30-fold its affinity for the VIP1 and PACAP I receptors. The introduction of an arginine residue in position 16, instead of glutamine, in VIP and PACAP had a similar effect: [R16] VIP and [R16] PACAP had 3- to 10-fold higher affinities than VIP and PACAP for VIP1 and PACAP I receptors, and 3-fold lower affinities for the secretin receptors. The three [R16] peptides also had a reduced potency on the chimeric receptor consisting of the N-terminal part of the secretin receptor grafted on the VIP1 receptor, and an enhanced potency on the chimeric receptor consisting of the N-terminal part of VIP1 receptor grafted on the secretin receptor, indicating that position 16 of each ligand interacted with the N-terminal extracellular domain of the receptors.
Collapse
MESH Headings
- Animals
- Arginine/physiology
- CHO Cells
- Cricetinae
- Ligands
- Neuropeptides/metabolism
- Pituitary Adenylate Cyclase-Activating Polypeptide
- Rabbits
- Rats
- Receptors, G-Protein-Coupled
- Receptors, Gastrointestinal Hormone/genetics
- Receptors, Gastrointestinal Hormone/metabolism
- Receptors, Peptide/metabolism
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Receptors, Pituitary Hormone/genetics
- Receptors, Pituitary Hormone/metabolism
- Receptors, Vasoactive Intestinal Peptide/genetics
- Receptors, Vasoactive Intestinal Peptide/metabolism
- Receptors, Vasoactive Intestinal Polypeptide, Type I
- Recombinant Fusion Proteins/metabolism
- Secretin/metabolism
- Swine
- Vasoactive Intestinal Peptide/metabolism
Collapse
Affiliation(s)
- P Gourlet
- Department of Biochemistry and Nutrition, Faculty of Medicine, Université Libre de Bruxelles, Belgium
| | | | | | | | | | | |
Collapse
|
326
|
Konttinen Y, Imai S, Suda A. Neuropeptides and the puzzle of bone remodeling. State of the art. ACTA ORTHOPAEDICA SCANDINAVICA 1996; 67:632-9. [PMID: 9065083 DOI: 10.3109/17453679608997772] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Bone metabolism is dependent on cells of the osteoblast and osteoclast lineage. These cells play a major role in the synthesis and degradation of osteoid and in its mineralization and demineralization. Bone cells are under the influence of various systemic and local auto/paracrine factors. One further regulatory element that can play both a sensory/ afferent and a regulatory/efferent role, consists of neuropeptide-containing nerves. In particular, the calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) have been implicated; their distribution in bone and their molecular biology are discussed in some detail. Bone neuropeptides can function as direct bone cell regulators, with additional amplifying indirect effects mediated by vascular endothelial cells, monocyte/macrophages and mast cells and their mediators. Recent experimental and clinical work has implicated bone nerves in processes varying from normal remodelling to fracture healing and non-union. Apart from systemic endocrine influences on bone stock and osteoclast/ osteoblast coupling (activation-resorption-formation cycle) mediated by local auto/paracrine factors, bone nerves/neuropeptides may explain why various inputs/outputs are transformed in a meaningful way to altered mass and quality of bone.
Collapse
Affiliation(s)
- Y Konttinen
- Department of Medicine, Helsinki University Central Hospital, Finland
| | | | | |
Collapse
|
327
|
Rawlings SR. Pituitary adenylate cyclase-activating polypeptide regulates [Ca(2+)](i) and electrical activity in pituitary cells through cell type-specific mechanisms. Trends Endocrinol Metab 1996; 7:374-8. [PMID: 18406775 DOI: 10.1016/s1043-2760(96)00187-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a recently identified hypothalamic factor that acts on a variety of anterior pituitary cell types. It is clear, however, that its actions are not mediated by the same intracellular signaling mechanisms in each cell type. The signaling pathways by which PACAP regulates changes in [Ca(2+)], and electrical activity in rat somatotrophs and gonadotrophs is described in the present article. Finally, the possibility that the differences in PACAP-regulated signaling in anterior pituitary cells is due to the differential expression and coupling of PACAP receptor subtypes is discussed.
Collapse
Affiliation(s)
- S R Rawlings
- Stephen R. Rawlings is at the Fondation pour Recherches Médicales, University of Geneva, CH-1211 Geneva, Switzerland
| |
Collapse
|
328
|
Yonezawa T, Furukawa Y, Lakhe M, Nagashima Y, Hirose M, Chiba S. PACAP-38 activates parasympathetic nerves in isolated, blood-perfused dog atria. Eur J Pharmacol 1996; 315:289-96. [PMID: 8982667 DOI: 10.1016/s0014-2999(96)00609-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A pituitary adenylate cyclase-activating polypeptide (PACAP) activates PACAP and vasoactive intestinal peptide (VIP) receptors. We investigated the effects of PACAP-38 on the sinus rate and atrial contractile force in isolated, blood-perfused dog heart preparations and the stimulation by PACAP-38 of the parasympathetic nerve fibers. PACAP-38 (3-1000 pmol) caused positive and/or negative chronotropic responses and it dose dependently increased atrial and ventricular contractile force. The positive cardiac responses to PACAP-38 unlike those to VIP were much less than the positive responses to norepinephrine. Atropine inhibited the negative chronotropic responses to PACAP-38 and augmented the positive chronotropic and inotropic responses. Physostigmine potentiated the negative cardiac responses to PACAP-38 and acetylcholine. After physostigmine treatment, additionally, tetrodotoxin blocked the negative cardiac responses to PACAP-38 and intracardiac parasympathetic nerve stimulation. Propranolol did not inhibit the positive cardiac responses to PACAP-38 in atropine-treated atria. PACAP-(6-38) (1 and 3 nmol), an antagonist of PACAP-38, did not affect the cardiac responses to 100 pmol of PACAP-38. These results suggest that (1) PACAP-38 directly increases sinus rate and atrial contractile force and (2) PACAP-38 activates parasympathetic nerves and causes negative chronotropic and inotropic responses in the dog heart.
Collapse
Affiliation(s)
- T Yonezawa
- Department of Pharmacology, Shinshu University School of Medicine, Nagano, Japan
| | | | | | | | | | | |
Collapse
|
329
|
Vertongen P, Camby I, Darro F, Kiss R, Robberecht P. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides 1996; 30:491-6. [PMID: 8923513 DOI: 10.1016/s0143-4179(96)90015-3] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Functional VIP/PACAP receptors were identified in the human glioblastoma cell line T98G, based on the relative potency of VIP, PACAP and PACAP-38 to stimulate adenylate cyclase activity. Analysis of the T98G cells mRNA by reverse transcription followed by a polymerase chain reaction (RT-PCR) demonstrated the expression of the mRNA coding for the VIP2 receptor subclass only. VIP, PACAP-27 and PACAP-38 were potent and efficIent inhibitors of cell proliferation, assessed by the colorimetric MTT assay. VIP, PACAP-27 and PACAP-38 also reduced the incorporation of 3H-thymidine in T98G cells, but did not significantly alter the percentage of cells present at each stage of the cell cycle. Thus, VIP and PACAP, probably acting through a VIP2 receptor subtype, decreased cell proliferation.
Collapse
Affiliation(s)
- P Vertongen
- Laboratoire de Chimie Biologique et de la Nutrition, Université Libre de Bruxelles, Belgium
| | | | | | | | | |
Collapse
|
330
|
Gourlet P, Vandermeers A, Vandermeers-Piret MC, De Neef P, Robberecht P. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1996; 48:391-6. [PMID: 8919060 DOI: 10.1111/j.1399-3011.1996.tb00856.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Chimeric peptides were synthesized by adding the C-terminal extension 28-38 of the pituitary adenylate cyclase activating polypeptide (PACAP) to the sequences (1-27), (2-27), (3-27) and (6-27) of VIP. The capacity of these peptides to occupy the selective PACAP- and the non-selective PACAP-VIP receptors and to stimulate adenylate cyclase activity was studied in chinese hamster ovary (CHO) cells expressing the recombinant receptors. The results were compared to those obtained with VIP and the corresponding VIP fragments. The presence of the (28-38) PACAP extension increased at least 100-fold the VIP- or VIP fragment affinities for the selective PACAP receptor but not for the non-selective PACAP-VIP receptors. Furthermore, on both receptors, the extension increased peptide intrinsic activity: VIP(3-28) was a partial agonist while VIP(3-27)/PACAP(28-38) was as potent as VIP and was apparently a full agonist; VIP(6-28) had no intrinsic activity, but VIP(6-27)/PACAP(28-38) was a partial agonist. These results suggest: (1) the presence of a specific domain for the (28-38) PACAP sequence on the selective PACAP receptor; and (2) a stabilizing effect of the (28-38) PACAP sequence on the structure of N-terminally truncated VIP.
Collapse
Affiliation(s)
- P Gourlet
- Laboratory of Biological Chemistry and Nutrition, Faculty of Medicine, Free University of Brussels, Belgium
| | | | | | | | | |
Collapse
|
331
|
Sheward WJ, Lutz EM, Harmar AJ. Expression of pituitary adenylate cyclase activating polypeptide receptors in the early mouse embryo as assessed by reverse transcription polymerase chain reaction and in situ hybridisation. Neurosci Lett 1996; 216:45-8. [PMID: 8892388 DOI: 10.1016/0304-3940(96)13002-0] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We have examined the expression of mRNA for the pituitary adenylate cyclase activating polypeptide (PACAP) receptor in the mouse from day 9.5 of embryonic development onwards by reverse transcription polymerase chain reaction (RT-PCR) and by in situ hybridisation. PACAP receptor mRNAs were detected by PCR in the earliest developmental stage examined and thereafter the levels of mRNA for all receptors increased during development. Wholemount in situ hybridisation first showed the expression of the PACAP receptor in the neural tube of 9.5 day old embryos, in later embryos heaviest expression of the PACAP receptor was found in the developing rhombencephalon (day 10.5 and 11.5). These results are consistent with a role for PACAP or a related peptide in the early development of the central nervous system.
Collapse
Affiliation(s)
- W J Sheward
- MRC Brain Metabolism Unit, Royal Edinburgh Hospital, UK
| | | | | |
Collapse
|
332
|
Pozo D, Guerrero JM, Segura JJ, Calvo JR. Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells. IMMUNOPHARMACOLOGY 1996; 34:113-23. [PMID: 8886855 DOI: 10.1016/0162-3109(96)00131-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Thymic peptide thymosin alpha 1 (10(-11) to 10(-6) M) is shown to interact with the VIP receptor-effector system in rat and mouse peritoneal macrophages, and both rat peripheral blood lymphocytes and spleen lymphocytes. In all models, thymosin alpha 1 inhibits 125I-VIP binding with a potency that is in a range 1000-1700 times lower than that of the native VIP. Interaction of thymosin alpha 1 with VIP receptors is compared with that of some structurally VIP-related peptides such as helodermin, PHI, secretin, and glucagon. The order of potency in inhibiting 125I-VIP binding was VIP > helodermin > PHI > secretin > thymosin alpha 1. Thymosin alpha 1 (10(-10) to 10(-6) M) was weak in stimulating adenylyl cyclase activity. Its efficacy is in a range 900-1800 times lower than that of native VIP in all cell types studied. The analysis of the sequence of both complete and N-terminal portion of thymosin alpha 1 reveals close structural and physicochemical similarities with the members of the so-called VIP family of polypeptides. Taken together, experimental data support that thymosin alpha 1 must be included like the lowest partial agonist of the VIP family of polypeptides and it is a VIP receptor antagonist with weak intrinsic activity.
Collapse
Affiliation(s)
- D Pozo
- Department of Medical Biochemistry and Molecular Biology, University of Seville School of Medicine, Spain
| | | | | | | |
Collapse
|
333
|
Palermo MS, Vermeulen ME, Giordano MN. Human antibody-dependent cellular cytotoxicity mediated by interferon gamma-activated neutrophils is impaired by vasoactive intestinal peptide. J Neuroimmunol 1996; 69:123-8. [PMID: 8823383 DOI: 10.1016/0165-5728(96)00078-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The aim of the present study was to evaluate the effect of vasoactive intestinal peptide (VIP) on the expression and activity of receptors for the Fc portion of IgG (Fc gamma R) in human neutrophils. Cells were assayed under basal conditions and following in vitro stimulation with interferon gamma (IFN gamma). Antibody dependent-cellular cytotoxicity (ADCC) was chosen as a means of evaluating Fc gamma R activity. The results indicated that incubation with VIP (10(-6) M) during 18 h slightly diminished cytotoxicity of non stimulated neutrophils. In contrast, VIP exerted a marked inhibitory effect on neutrophils activated with IFN gamma. Similar results were obtained with forskolin, another agent that increases intracellular cAMP. Finally, using monoclonal antibodies and flow cytometry analysis, we found decreased membrane expression of Fc gamma R after VIP incubation. Taken together, these results show that VIP is able to act on human neutrophils, partially blocking IFN gamma-activation of Fc gamma R mediated functions. Modulation of neutrophil cytotoxic response by VIP may have an important role in limiting tissue injury during inflammation.
Collapse
Affiliation(s)
- M S Palermo
- Division of Immunology, National Academy of Medicine, Buenos Aires, Argentina
| | | | | |
Collapse
|
334
|
Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K, Matsuda T, Mizuno N, Nagata S, Baba A. Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 1996; 371:567-77. [PMID: 8841910 DOI: 10.1002/(sici)1096-9861(19960805)371:4<567::aid-cne6>3.0.co;2-2] [Citation(s) in RCA: 167] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PACAP-R) was examined in the rat brain, and also in the hypophysis and pineal gland, by in situ hybridization with a specific 35S-labeled riboprobe which was generated from a rat PACAP-R cDNA clone. In the brain, expression of PACAP-R mRNA was most prominent in the periglomerular and granule cells of the olfactory bulb, granule cells of the dentate gyrus, supraoptic nucleus, and area postrema. The expression was also intense in the piriform, cingulate, and retrosplenial cortices, pyramidal cells in CA2, non-pyramidal cells in CA1-CA3, neuronal cells in the hilus of the dentate gyrus, lateral septal nucleus, intercalated amygdaloid nucleus, anterodorsal thalamic nucleus, most of the midline and intralaminar thalamic nuclei, many regions of the hypothalamus, dorsal motor nucleus of the vagus nerve, hypoglossal nucleus, and lateral reticular nucleus. No significant expression was detected in the mitral and tufted cells in the olfactory bulb, pyramidal cells in CA1 and CA3, posterior nuclear group of the thalamus, dorsal lateral geniculate nucleus, and Purkinje, Golgi, and granule cells in the cerebellar cortex. Moderate-to-weak expression was further observed in many other regions of the brain. In the cerebellar cortex, presumed Bergmann glia cells showed moderate expression. In the hypophysis, the expression was moderate in the anterior lobe, and weak to moderate in the posterior lobe; no significant expression was observed in the intermediate lobe. In the pineal gland, the expression was very weak, if any. Thus, the expression of PACAP-R was detected not only on neuronal cells but also on some particular glial cells. The present study has shown, for the first time, the exact site of PACAP-R expression in the brain and hypophysis. Although the functional significance of PACAP and PACAP-R in the brain still remains to be clarified, the present results are considered to provide some direction for future functional studies.
Collapse
Affiliation(s)
- H Hashimoto
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Osaka University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
335
|
Delgado M, Martinez C, Johnson MC, Gomariz RP, Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 1996; 68:27-38. [PMID: 8784257 DOI: 10.1016/0165-5728(96)00063-x] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Vasoactive intestinal peptide (VIP), a neuropeptide present in the lymphoid microenvironment, modulates cytokine expression and affects T cell proliferation. Recent molecular studies identified two VIP receptors. VIP-R1 and VIP-R2, primarily in nonlymphoid cells. In this study, we investigate the expression of VIP-R1 and VIP-R2 mRNA in unstimulated and stimulated lymphocytes and thymocytes, and in various lymphocyte subpopulations. In contrast to VIP-R1 which is constitutively expressed, the expression of VIP-R2 is induced only following stimulation through the TCR-associated CD3 complex. Both CD4+ and CD8+ T cells express VIP-R1 and VIP-R2. Two T cell lines, EL-4.IL-2 and D10.G4.1 express exclusively VIP-R2. VIP induces the expression of the VIP-R2 gene in the absence of additional stimuli. Differential expression and regulation of the two VIP receptors in T lymphocytes suggests different physiological roles in mediating the immunomodulatory activities of VIP and related neuropeptides.
Collapse
Affiliation(s)
- M Delgado
- Department of Biological Sciences, Rutgers University, Newark, NJ 07102, USA
| | | | | | | | | |
Collapse
|
336
|
Pei L. Identification of a Negative Glucocorticoid Response Element in the Rat Type 1 Vasoactive Intestinal Polypeptide Receptor Gene. J Biol Chem 1996. [DOI: 10.1074/s0021-9258(19)73912-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
337
|
Johnson MC, McCormack RJ, Delgado M, Martinez C, Ganea D. Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J Neuroimmunol 1996; 68:109-19. [PMID: 8784267 DOI: 10.1016/0165-5728(96)00085-9] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Vasoactive intestinal peptide (VIP), a neuropeptide present in primary and secondary lymphoid organs has been previously reported to inhibit IL-2 and IL-4 production as well as the proliferation of mitogen- or antigen-stimulated T-cells. Binding studies suggested that the immunoregulatory effects of VIP are mediated through specific VIP-binding sites present on lymphocyte subpopulations. Here we report on the expression of VIP-R1 mRNA in various murine lymphocyte subpopulations. By using RT-PCR. RNase protection assay, cDNA cloning, and sequence analysis, we show that stimulated and unstimulated murine spleen cells, thymocytes. CD4+ and CD8+ T-cells express VIP-R1. The VIP-R1 fragment amplified from murine brain, thymocytes, spleen cells and CD4+ T-cells share identical nucleotide sequences, and a high degree of homology with the corresponding nonlymphoid rat and human VIP-R1 sequences. The expression of VIP-R1 in thymocytes and peripheral lymphocytes, and especially in the CD4+ T-cell subset supports the idea that VIP produced or released locally in the lymphoid microenvironment could directly affect cytokine production and proliferation of T-lymphocytes.
Collapse
MESH Headings
- Animals
- Blotting, Northern
- Blotting, Southern
- Brain/cytology
- CD4-Positive T-Lymphocytes/chemistry
- CD4-Positive T-Lymphocytes/physiology
- CD8-Positive T-Lymphocytes/chemistry
- CD8-Positive T-Lymphocytes/physiology
- Female
- Lung/cytology
- Mice
- Mice, Inbred BALB C
- Molecular Sequence Data
- Polymerase Chain Reaction
- RNA, Messenger/immunology
- RNA, Messenger/metabolism
- Receptors, Vasoactive Intestinal Peptide/genetics
- Receptors, Vasoactive Intestinal Polypeptide, Type I
- Sequence Analysis, DNA
- Sequence Homology, Nucleic Acid
- Spleen/cytology
- Thymus Gland/cytology
Collapse
Affiliation(s)
- M C Johnson
- Department of Biological Sciences, Rutgers University, New York, NJ 07102, USA
| | | | | | | | | |
Collapse
|
338
|
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996; 23:685-92. [PMID: 8940711 DOI: 10.1016/0969-8051(96)00066-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Recent data suggest that functional receptors (R) for vasoactive intestinal peptide (VIP) are expressed on various tumor cells. The high-level expression of VIPR on tumor cells provided the basis for the successful use of 123I-labeled VIP for the in vivo localization of intestinal adenocarcinomas and endocrine tumors. We here report an update of our imaging results using 123I-VIP (150-200 MBg/1 microgram/patient) in 169 patients. In patients with pancreatic adenocarcinomas without liver metastases, the primary/recurrent tumor was visualized in 16 of 18 patients (89%) and liver metastases were imaged in 15 of 16 patients. In 11 of 12 patients with colorectal adenocarcinomas, the primary/recurrent tumor (92%) was imaged by 123I-VIP. Also, in 21 of 25 patients, liver metastases (84%); in 3 of 6 patients, lung metastases (50%); and in 4 of 5 patients, lymph-node metastases (80%) were imaged by 123I-VIP. In 10 of 10 patients with gastric adenocarcinomas, the primary/recurrent tumor; in 3 of 4 patients, liver metastases; and in 2 of 2 patients, lymph-node metastases were visualized by 123I-VIP. 123I-VIP localized primary intestinal carcinoid tumors in 15 of 17 patients (88%) and 8 of 10 primary insulinomas (80%). We conclude that the 123I-VIPR scintigraphy localizes intestinal adenocarcinomas and endocrine tumors as well as metastatic tumor sites.
Collapse
Affiliation(s)
- I Virgolini
- Department of Nuclear Medicine, University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
339
|
Fahrenkrug J, Hannibal J. Pituitary adenylate cyclase activating polypeptide innervation of the rat female reproductive tract and the associated paracervical ganglia: effect of capsaicin. Neuroscience 1996; 73:1049-60. [PMID: 8809823 DOI: 10.1016/0306-4522(96)00082-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Pituitary adenylate cyclase activating peptide (PACAP) is a novel vasoactive intestinal polypeptide-like peptide which is present in neuronal elements of a number of peripheral organs. PACAP occurs in two forms, PACAP-27 and the C-terminally extended PACAP-38, both derived from the same precursor which in addition gives rise to a structurally-related peptide, PACAP-related peptide. Using specific radioimmunoassays for PACAP-38, PACAP-27 and PACAP-related peptide we found that the three PACAP-precursor-derived peptides were present in tissue extracts from all regions of the rat female genital tract. PACAP-38 was the dominating peptide with the highest concentrations in the Fallopian tube and the ovary. Upon reverse phase high pressure liquid chromatography the immunoreactive material was found to co-elute with synthetic PACAP-38, PACAP-27 and PACAP-related peptide, respectively. By immunohistochemistry, PACAP was shown to be located in varicose nerve fibres associated with blood vessels, smooth muscle and epithelial cells. Within the local paracervical ganglion PACAP-immunoreactive fibres ramified often forming varicose, pericellular plexuses around non-PACAP-positive cell bodies. Also bundles of PACAP-immunoreactive fibres were transversing the ganglion. In the paracervical ganglion of normal rat only a few neuronal cell bodies showed immunostaining for PACAP, but after local colchichine-treatment a moderate number of positive perikarya appeared. The synthesis of PACAP in neurons of the paracervical ganglia was confirmed by in situ hybridization histochemistry with a digoxigenin-labelled cRNA probe. Double immunostaining for PACAP and vasoactive intestinal polypeptide disclosed a partial co-existence of the two peptides in nerve fibres of all tubular organs in the rat female genital tract and in cell bodies and nerve fibres in the paracervical ganglion. After neonatal capsaicin treatment the concentration of immunoreactive PACAP-38 as well as the number and intensity of PACAP-positive nerve fibres were reduced while vasoactive intestinal polypeptide immunoreactivity was unaffected. In conclusion, PACAP-immunoreactive nerve fibres have been demonstrated in all regions of the rat female genital tract associated with blood vessels, smooth musculature and epithelium. In some fibres, which seem to originate in the local paracervical ganglia, PACAP was co-localized with vasoactive intestinal polypeptide. PACAP released from these fibres could alone or in concert with vasoactive intestinal polypeptide play a role in neuroregulation of female reproductive organs acting directly on the musculature and vasculature. Other PACAP-containing fibres are sensory in nature, and some of these might influence ganglionic neurotransmission in the local paracervical ganglia.
Collapse
Affiliation(s)
- J Fahrenkrug
- Department of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, Denmark
| | | |
Collapse
|
340
|
Pozo D, Segura JJ, Carrero I, Guijarro LG, Prieto JC, Calvo JR. Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes. BIOCHIMICA ET BIOPHYSICA ACTA 1996; 1312:249-54. [PMID: 8703995 DOI: 10.1016/0167-4889(96)00044-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Vasoactive intestinal peptide (VIP) stimulated adenylyl cyclase activity in rat and mouse peritoneal macrophage membranes. GTP potentiated the stimulatory effect of VIP so that it was routinely included at 10 microM GTP. Other agents like GTP, Gpp(NH)p, GTP-gamma-S, sodium fluoride, and forskolin, at a concentration of 0.1 mM, increased the basal activity of enzyme by 3.1, 5.7, 4.7, 3.6, and 7.8-fold, respectively. The stimulation of adenylyl cyclase by VIP was time, temperature, and membrane concentration dependent. Half-maximal enzyme activation (ED50) was very similar in rat and mouse peritoneal macrophage membranes (1.5 +/- 0.1 nM and 1.0 +/- 0.1 nM, respectively). However, VIP showed more efficacy in mouse macrophages membranes (about 3.1-fold basal values) than that in rat macrophage membranes (about 2.5-fold basal values). The relative potency of several peptides upon stimulation of adenylyl cyclase activity showed the following potency in both species: VIP = PACAP38 = PACAP27 > helodermin > PHI > secretin. On the other hand, a M(r)-45 kDa alpha s subunit of Gs protein was demonstrated by both ADP-ribosylation and immunoblot in mouse and rat peritoneal macrophage membranes. The present results, together other previous, strongly suggest that VIP play an important role in the regulation of macrophage function.
Collapse
Affiliation(s)
- D Pozo
- Departmento de Bioquímica Médica y Biología Molecular, Facultad de Medicina, Universidad de Sevilla, Spain
| | | | | | | | | | | |
Collapse
|
341
|
Pisegna JR, Wank SA. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 1996; 271:17267-74. [PMID: 8663363 PMCID: PMC6721843 DOI: 10.1074/jbc.271.29.17267] [Citation(s) in RCA: 161] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Alternative splicing of two exons of the rat pituitary adenylate cyclase activating polypeptide (PACAP) receptor gene generates four major splice variants that are differentially expressed in specific tissues and variably coupled to intracellular second messengers. To evaluate the potential implications of these findings in human physiology, the human PACAP receptor gene was cloned. Alternative splicing about two exons of the gene allowed for four major splice variants that were subsequently identified on cDNA cloning. Each of the four splice variant cDNAs (null, SV-1, SV-2, and SV-3) was stably expressed in NIH/3T3 cells at similar receptor densities. For each splice variant, PACAP (both PACAP-38 and PACAP-27) had similar affinity and potency for stimulating either adenylate cyclase or phospholipase C. However, each receptor splice variant differed in their ligand-stimulated maximal response (efficacy) for total inositol phosphate accumulation with the SV-2 showing the greatest efficacy, followed by the null, SV-1, and SV-3 splice variants. Therefore, unlike the rat, PACAP binds and stimulates signal transduction with nearly equal affinity and potency for each of the receptor splice variants although with varying efficacy for the stimulation of phospholipase C. These results suggest a novel and potentially important mechanism for a single hormone to not only couple to dual signal transduction cascades but also elicit tissue-specific differential activation of phospholipase C in humans.
Collapse
Affiliation(s)
- J R Pisegna
- Digestive Diseases Branch, National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | |
Collapse
|
342
|
Gourlet P, Vilardaga JP, De Neef P, Vandermeers A, Waelbroeck M, Bollen A, Robberecht P. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor. EUROPEAN JOURNAL OF BIOCHEMISTRY 1996; 239:349-55. [PMID: 8706739 DOI: 10.1111/j.1432-1033.1996.0349u.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The ability of secretin, PACAP-(1-27)-peptide, and ten hybrid peptides to recognize and activate the rat secretin and vasoactive intestinal polypeptide (PACAP type II VIP1) receptors was tested on recombinant Chinese hamster ovary (CHO) cell lines. PACAP had a 2500-fold lower affinity than secretin for the secretin receptor, and secretin had a 300-fold lower affinity than PACAP for the VIP1 receptor. Amino acids 8, 13, and 15 of the PACAP molecule contributed significantly to the low affinity of PACAP for the secretin receptor. The amino acids at positions 5, 9, 10, 15, 16, and unidentified amino acid(s) between positions 17-20 made limited contributions to the low affinity of secretin for the VIP1 receptor. To identify the receptor region that interacts with these amino acids, we constructed chimeric receptors, which consist either of the N-terminal extracellular part of the secretin receptor and the core of the VIP1 receptor (N-Sn/VIP1r) or the N-terminal extracellular part of the VIP1 receptor and the core of the secretin receptor (N-VIP1/Snr), and tested the ability of the hybrid ligands to activate the adenylate cyclase of CHO cells expressing these chimeric receptors. The N-Sn/VIP1 receptors had a higher affinity for secretin than for PACAP. The hybrid peptide 6 that consists of the PACAP-(1-8)-Sn-(9-15)-PACAP-(16-27)-peptide sequence had a 30-fold to 200-fold higher potency than either parent peptide for the chimeric receptor, which suggests that while the N- and/or C-terminal part of the peptide interact with the transmembrane domain of the receptor, the discriminator region 9-15 recognizes the extracellular N-terminal domain of the receptor. This was confirmed by the observation that, out of all the peptides tested, hybrid 6 had the weakest potency for activation of the N-VIP1/Sn chimeric receptors.
Collapse
Affiliation(s)
- P Gourlet
- Department of Biochemistry and Nutrition, School of Medicine, Université Libre de Bruxelles, Belgium
| | | | | | | | | | | | | |
Collapse
|
343
|
Moller K, Sundler F. Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. REGULATORY PEPTIDES 1996; 63:129-39. [PMID: 8837221 DOI: 10.1016/0167-0115(96)00033-x] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) which belongs to the vasoactive intestinal polypeptide family of regulatory peptides, occurs in two variants, PACAP-27 and PACAP-38, and is thought to be an important messenger in both the central and peripheral nervous system. Three cloned G-protein coupled 7 transmembrane spanning receptors bind PACAP with high affinity, one reacting only weakly with VIP (PACAP type I receptor) the other two binding vasoactive intestinal peptide (VIP) with equally high affinity (VIP type I and II receptors). The PACAP type I receptor displays high affinity for both variants of PACAP. In this study, we have investigated the distribution of PACAP and the PACAP type I receptor in the adrenal medulla of newborn and adult rat. Immunocytochemistry revealed, in the adult rat, a dense network of PACAP-immunoreactive nerve fibers terminating on chromaffin cells. Such fibers were few and weakly immunoreactive in the newborn rat. PACAP-immunoreactive medullary cells could not be detected in the adult rat, whereas in the newborn, occasional cells were seen. By in situ-hybridization we detected PACAP type I receptor mRNA in a majority of the adrenal medullary cells of both newborn and adult rat. Receptor autoradiography using 125I-PACAP-27 as ligand revealed binding-sites with a localization virtually identical to the in situ hybridization signal indicating a functional expression of high-affinity type I PACAP receptors in the adrenal medulla. Additionally, in the adult rat, single or clustered large cells, presumably ganglion cells, contained an even higher abundance of PACAP receptor mRNA as well as binding sites than the surrounding chromaffin cells. Our observations on the distribution of PACAP peptide and PACAP receptors in the adrenal medulla suggest that both chromaffin cells and ganglion cells are PACAP targets. The data thus strengthen earlier observations indicating an important regulatory role of PACAP in catecholamine biosynthesis and release. The presence of both ligand and receptors in newborn rats may indicate a role for PACAP in the development of the adrenal medulla.
Collapse
Affiliation(s)
- K Moller
- Department of Physiology and Neuroscience, Neuroendocrine Cell Biology, Lund University, Sweden
| | | |
Collapse
|
344
|
Shima K, Sakakibara H, Said SI. Characterization of VIP-and helodermin-preferring receptors on rat platelets. REGULATORY PEPTIDES 1996; 63:99-103. [PMID: 8837217 DOI: 10.1016/0167-0115(96)00026-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We have examined the binding of radio-iodinated vasoactive intestinal peptide (VIP) to rat platelets. The binding was time- and temperature-dependent and was reversible, saturable and specific. Scatchard analysis of binding data suggested the presence of a single class of binding sites, with Kd = 2.49 +/- 0.76 nM and Bmax = 112.1 +/- 54.6 fmol/10(8) cells. Several VIP-related peptides inhibited 125I-VIP binding to rat platelets with the following order of potency: helodermin > or = VIP > peptide histidine isoleucine. Glucagon, secretin, growth hormone-releasing hormone (GHRH), and gastric inhibitory peptide (GIP) were ineffective. VIP and the other peptides increased cyclic AMP production with the same order of potency as the inhibition of binding, but the stimulation by VIP was less marked than that by prostacyclin (PGI2). We conclude that rat platelets have functional, adenylate cyclase-linked, receptors that bind preferentially to helodermin and VIP.
Collapse
Affiliation(s)
- K Shima
- First Department of Internal Medicine, Nagoya University School of Medicine, Aichi, Japan
| | | | | |
Collapse
|
345
|
Hashimoto H, Yamamoto K, Hagigara N, Ogawa N, Nishino A, Aino H, Nogi H, Imanishi K, Matsuda T, Baba A. cDNA cloning of a mouse pituitary adenylate cyclase-activating polypeptide receptor. BIOCHIMICA ET BIOPHYSICA ACTA 1996; 1281:129-33. [PMID: 8664310 DOI: 10.1016/0005-2736(96)00056-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A cDNA clone for mouse pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PACAP-R) was obtained from the brain using reverse transcription-polymerase chain reaction (RT-PCR). The recombinant PACAP receptor expressed in COS cells bound PACAP with about 1000-times higher affinity than vasoactive intestinal polypeptide (VIP), and PACAP stimulated adenylate cyclase through the cloned PACAP receptor. The mouse PACAP receptor consists of 496 amino acids, contains seven transmembrane segments and has 98.4%, 93.0%, and 92.5% identity with the rat, bovine, and human PACAP-R, respectively.
Collapse
Affiliation(s)
- H Hashimoto
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Osaka University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
346
|
Draoui M, Hida T, Jakowlew S, Birrer M, Zia F, Moody TW. PACAP stimulates c-fos mRNAs in small cell lung cancer cells. Life Sci 1996; 59:307-13. [PMID: 8761002 DOI: 10.1016/0024-3205(96)00299-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The effects of PACAP on c-fos mRNA using small cell lung cancer (SCLC) cell was investigated. PACAP-27 (100 nM) increased c-fos mRNA 5-fold using NCI-N417 cells. The increase was concentration dependent with 0.1 nM PACAP-27 half maximally increasing c-fos mRNA. Also the increase in c-fos mRNA caused by PACAP was time dependent; being maximal after 1 hour and returning to basal values after 4 hours. PACAP-38 but not PACAP(28-38) increased c-fos mRNA. One uM PACAP(6-38), a PACAP receptor antagonist, inhibited the increase in c-fos mRNA caused by 1 nM PACAP. These data indicate that PACAP stimulates nuclear oncogene expression in SCLC cells.
Collapse
Affiliation(s)
- M Draoui
- Dept. Microbiology, George Washington Univ. Med., Ctr., Washington, DC 20037, USA
| | | | | | | | | | | |
Collapse
|
347
|
Gardella TJ, Luck MD, Fan MH, Lee C. Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J Biol Chem 1996; 271:12820-5. [PMID: 8662729 DOI: 10.1074/jbc.271.22.12820] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Polar residues within the transmembrane domains (TMs) of G protein-coupled receptors have been implicated to be important determinants of receptor function. We have identified mutations at two polar sites in the TM regions of the rat parathyroid hormone (PTH)/PTH-related peptide receptor, Arg-233 in TM 2 and Gln-451 in TM 7, that caused 17-200-fold reductions in the binding affinity of the agonist peptide PTH-(1-34) without affecting the binding affinity of the antagonist/partial agonist PTH-(3-34). When mutations at the TM 2 and TM 7 sites were combined, binding affinity for PTH-(1-34) was restored to nearly that of the wild type receptor. The double mutant receptors, however, were completely defective in signaling cAMP or inositol phosphate production in response to PTH-(1-34) agonist ligand. The results demonstrate that Arg-233 and Gln-451 have important roles in determining agonist binding affinity and transmembrane signaling. Furthermore, the finding that residues in TM 2 and TM 7 are functionally linked suggests that the TM domain topology of the PTH/PTH-related peptide receptor may resemble that of receptors in the rhodopsin/beta-adrenergic receptor family, for which structural and mutagenesis data suggest interactions between TMs 2 and 7.
Collapse
Affiliation(s)
- T J Gardella
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
| | | | | | | |
Collapse
|
348
|
Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, Laburthe M. Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 1996; 271:12795-800. [PMID: 8662697 DOI: 10.1074/jbc.271.22.12795] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Vasoactive intestinal peptide (VIP)1 receptors in rats and humans recognize peptide histidine isoleucineamide (PHI) with high and low affinity, respectively. We took advantage of this phenotypic difference to identify the domain responsible for the selective recognition of PHI by rat and human receptors which display >80% sequence identity. After transfection of human and rat receptors in COS cells, the ratio of IC50 for PHI/IC50 for VIP (referred to as P/V) in inhibiting 125I-VIP binding was shown to be >1,000 and <40, respectively. Construction of eight rat/human receptor chimerae by overlap polymerase chain reaction and determination of their P/V ratios demonstrated that the critical domain for PHI recognition is present within a sequence comprising part of the first extracellular loop and third transmembrane domain. This domain contains three different amino acids numbered according to human and rat sequences, respectively, e.g. Gln207 (human) versus His208 (rat), Gly211 versus Ala212 and Met219 versus Val220. Site-directed mutagenesis introducing individual, double, or triple mutations in a chimeric construct revealed that all three amino acids were involved in the recognition of PHI. Triple mutations were then introduced in the wild-type receptors i.e. Q207H, G211A, M219V human VIP1 receptor and H208Q, A212G, V220M rat VIP1 receptor, resulting in a complete change in their phenotype from human to rat and from rat to human, respectively. The results demonstrate that three nonadjacent amino acids are responsible for the selective recognition of PHI by human and rat VIP1 receptors.
Collapse
Affiliation(s)
- A Couvineau
- Unité de Recherche de Neuroendocrinologie et Biologie Cellulaire Digestives, Institut National de la Santé et de la Recherche Médicale, INSERM U410, Faculté de Médecine Xavier Bichat, BP 416, 75870 Paris Cedex 18, France
| | | | | | | | | | | |
Collapse
|
349
|
Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur J Pharmacol 1996; 302:207-14. [PMID: 8791009 DOI: 10.1016/0014-2999(96)00096-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We stably transfected Chinese hamster ovary (CHO) cells with the recombinant human vasoactive intestinal peptide (VIP)1 receptor. A clone referred to as Clone 15 was isolated and studied for receptor properties. The following data were obtained: (1) one class of binding site was identified by Scatchard analysis of [125I]VIP binding to cell membranes with a Kd of 0.41 nM and a Bmax of 1.62 pmol/mg protein; (2) the constant Ki for the inhibition of [125I]VIP binding by VIP and related peptides was: VIP (0.9 nM) = pituitary adenylate cyclase-activating peptide (PACAP)-27 (1.3 nM) < PACAP-38 (6.8 nM) < helodermin (46.0 nM) < human growth hormone-releasing factor (GRF) (0.6 microM) < peptide histidine methionineamide (2.0 microM) < secretin (> 10 microM); (3) cross-linking experiments using [125I]VIP identified a single M(r) 67000 recombinant receptor; (4) VIP stimulated cAMP production in Clone 15 cells with an EC50 of 0.20 nM; (5) some previously described VIP receptor antagonists including [4-Cl-D-Phe6, Leu17]VIP, [Ac-Tyr1,D-Phe2]GRF-(1-29) amide and VIP-(10-28) inhibited [125I]VIP binding with a Ki of 0.7, 1.6 and 2.5 microM, respectively. They failed to stimulate cAMP production in Clone 15 cells and inhibited, at least partially, the VIP (0.3 nM)-evoked cAMP production; (6) exposure of Clone 15 cells to 10 nM VIP for 24 h resulted in a sharp decrease in Bmax in Clone 15 cells (0.43 vs. 1.62 pmol/mg protein in control cells) and in the potency and efficacy of VIP in stimulating cAMP. Moreover, immunofluorescence studies using confocal microscopy indicated that the receptor was internalized and sequestered in vesicular structures within the cells. It is concluded that Clone 15 cells provide a valuable tool to further characterize various functional and pharmacological aspects of the human VIP1 receptor.
Collapse
Affiliation(s)
- P Gaudin
- Institut National de la Santé et de la Recherche Médicale, INSERM U 410, Faculté de Médecine Xavier Bichat, Paris, France
| | | | | | | | | |
Collapse
|
350
|
Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathé J, De Neef P, Robberecht P. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors. REGULATORY PEPTIDES 1996; 62:125-30. [PMID: 8795075 DOI: 10.1016/0167-0115(96)00010-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) analogues were tested for their ability to occupy the recombinant selective PACAP receptors (PACAP type I receptors) and the non-selective PACAP-vasoactive intestinal polypeptide (VIP) receptors (PACAP type II, VIP1 and PACAP type II, VIP2 receptors), stably transfected and expressed in Chinese hamster ovary cells. Their capacity to stimulate the adenylate cyclase activity was also measured. The synthetic analogues tested were peptides shortened at the carboxyl terminus by the removal of 1-4 amino acids (PACAP-26 to PACAP-23). All the peptides discriminated the 3 receptor subtypes and had the highest affinity for the VIP1 receptors, and the lowest affinity for the VIP2 receptors; PACAP-25 having the highest ability to discriminate the VIP1 and VIP2 receptors. All the peptides tested were full agonists on the PACAP I and VIP1 receptors; PACAP-25 and -26 were partial agonists on VIP2 receptors and may be appropriate tools to establish the receptor subtype involved in a given cellular response.
Collapse
Affiliation(s)
- P Gourlet
- Department of Biochemistry and Nutrition, School of Medicine, Université Libre de Bruxelles, Belgium
| | | | | | | | | | | |
Collapse
|